Nutra Pharma Announces Publication of Research Report by Cohen Independent Research Group

• Press Release
• Source: Nutra Pharma Corp.
• On 2:48 pm EDT, Thursday October 22, 2009

PLANTATION, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB: NPHC - News), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that Cohen Independent Research Group has published a report profiling Nutra Pharma Corporation. The report, which was commissioned by Nutra Pharma, focuses on the company’s current drug development initiatives, including the company’s leading drug candidates for the treatment of Multiple Sclerosis (MS), HIV, Adrenomyeloneuropathy (AMN), and Rheumatoid Arthritis (RA) as well as the company’s recent launch of Cobroxin for the treatment of chronic pain.

Related Quotes

Symbol	Price	Change
NPHC.OB	0.43	+0.01

{"s" : "nphc.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

A PDF of the research report can be accessed at: http://www.cohenresearch.com/reports/nphc_10-21-09.pdf

About Cohen Independent Research Group

Led by Paul Cohen, Cohen Independent Research Group is one of Wall Street's leading independent research firms. As the founder of the Bear Stearns Western Regional Offices, Paul Cohen was one of the original 12 Dirty Dozen analysts regarded by many to be the top 12 security analysts in the nation. Mr. Cohen was also the West Coast Senior Vice President of CBWL-Hayden Stone-American Express. Over the years, Mr. Cohen's partners included Sanford Weill, the past Chairman and CEO of Citigroup and the past Chairman of Solomon Smith Barney, as well as Arthur Levitt, the past Chairman of the Securities and Exchange Commission (SEC).

The Cohen Independent Research Group includes nine PhDs (three with MDs), two MDs, six CFAs, three CPAs and 21 analysts covering most industries.

http://www.CohenResearch.com

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's subsidiary, ReceptoPharm, Inc., is developing these technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics, is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Paratuberculosis (para-TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

http://www.NutraPharma.com

http://www.ReceptoPharm.com

http://www.Cobroxin.com

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the publication of the research report by Cohen Independent Research Group should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Nutra Pharma Corp.
David Isserman, 877-895-5647
IR@nutrapharma.com